Скачать или смотреть EV-103 Cohort K: long-term outcomes of EV ± pembrolizumab in la/mUC

Terence Friedlander, MD, University of California, San Francisco, CA, discusses updated results from Cohort K of the Phase Ib/II EV-103 study (NCT03288545), which assessed enfortumab vedotin (EV) with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). With a median follow-up of around 3.5 years, EV plus pembrolizumab maintained high and durable response rates, prolonged progression-free and overall survival, and showed manageable safety, reinforcing its role as a first-line standard of care in this setting. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.